Effect of Counterions on Physicochemical Properties of Prazosin Salts
- 390 Downloads
This study evaluated the effect of counterions on the physicochemical properties of prazosin salts. Salt forms of prazosin, namely, mesylate, besylate, tosylate, camsylate, oxalate, and maleate, were prepared and compared with the marketed anhydrous and polyhydrate forms of prazosin hydrochloride. Physicochemical characterization was performed in the order of crystallinity, hygroscopicity, solubility, and stability to select the optimal salt(s). Permeability study in Caco-2 cell lines and in vivo bioavailability study in rat model were investigated to ascertain their biopharmaceutical advantage. All salt forms were crystalline, nonhygroscopic (except the anhydrous hydrochloride salt), and had solubility in the range of 0.2 to 1.6 mg/ml. All salts were physically and chemically stable at 40°C/75% relative humidity, but degraded in UV-visible light, except the anhydrous hydrochloride salt. Prazosin mesylate was selected as the optimal salt, as it possessed higher solubility, permeability, and bioavailability, compared to the commercial hydrochloride salts. Hydrochloride salt is reported to have poor bioavailability that is partially attributed to its low solubility and extensive common-ion effect in the gastric region. Factors like hydrophilicity of the counterion, hydration state of the salt, and melting point of the salt contribute to the physicochemical properties of the salts. This study has implications in the selection of an optimal salt form for prazosin, which is suitable for further development.
KEY WORDSprazosin preformulation salt form salt screening
Lokesh Kumar acknowledges the Department of Science and Technology of the Government of India and the Ranbaxy Science Foundation for providing the research fellowship to carry out this work. Services provided by the Central Instrumentation Laboratory at NIPER Mohali are also gratefully acknowledged.
Declaration of Interest
The authors report no conflict of interest. The authors alone are responsible for the content and writing of the paper.
- 3.Bowker MJ. A procedure for salt selection and optimization. In: Stahl PH, Wermuth CG, editors. Handbook of pharmaceutical salts: properties, selection and use. Weinheim: Wiley-VCH Inc.; 2002. p. 161–89.Google Scholar
- 4.Davies G. Changing the salt, changing the drug. Pharm J. 2001;266:322–3.Google Scholar
- 7.Stahl PH, Nakano M. Pharmaceutical aspects of the drug salt form. In: Stahl PH, Wermuth CG, editors. Handbook of pharmaceutical salts: properties, selection and use. Weinheim: Wiley-VCH Inc.; 2002. p. 83–116.Google Scholar
- 10.Gilman AG, Goodman LS, Gilman A. Goodman and Gilman’s the pharmacological basis of therapeutics. 6th ed. New York: McMillan; 1980. p. 806–7.Google Scholar
- 11.Hofmann BB. Adrenergic receptor blocking agents. In: Katzung BG, editor. Basic and clinical pharmacology. Los Altos: Lange Medical; 1984. p. 97–107.Google Scholar
- 13.Bianco EJ. Novel crystalline forms of prazosin hydrochloride. US Patent 4092315; 1978.Google Scholar
- 14.Kostek LJ. Prazosin hydrochloride. In: Brittain HG, editor. Analytical profile of drug substances and excipients, vol. 18. Amsterdam: Elsevier; 1989. p. 351–81.Google Scholar
- 16.Kostek LJ. Prazosin hydrochloride. Analytical Profile of Drug Substances and Excipients. 1989;18:351–81.Google Scholar
- 17.Prazosin permeability. http://www.cyprotex.com/cloescreen/in-vitro-permeability/mdr1-mdck-permeability/. Accessed 1 May 2012.
- 18.Bianco EJ. Novel crystalline forms of prazosin hydrochloride. US Patent 4092315, Pfizer Inc.; 1978.Google Scholar
- 21.Tong W. Salt screening and selection: new challenges and considerations in the modern pharmaceutical R&D paradigm. http://www.pharmacy.utah.edu/pharmaceutics/pdf/Salt.pdf. Accessed 5 May 2012.
- 22.MDR1–MDCK permeability (P-glycoprotein substrate identification). http://www.cyprotex.com/cloescreen/in-vitro-permeability/mdr1-mdck-permeability/. Accessed 1 May 2012.
- 26.Bowker MJ, Stahl PH. Preparation of water-soluble compounds through salt formation. In: Wermuth CG, editor. The practice of medicinal chemistry. London: Academic; 2008. p. 749–66.Google Scholar